AVTR Stock Analysis — Avantor
Sector: Healthcare
AI Verdict
AVTR is cheap for the stability its supply chain moat offers, but the negative growth means the low price is justified until demand turns.
Competitive Moat
Avantor supplies mission-critical chemicals and consumables for life sciences and biopharma, embedding itself in customer workflows with high switching costs. Its defensibility comes from integrated logistics and proprietary formulations that are hard for labs and manufacturers to replicate or replace quickly.
Summary
AVTR is notable for trading at just 9.7x next year's earnings despite being a core supplier to pharma and biotech labs.
Where It Stands
With a forward P/E of 9.7x—less than half the healthcare sector median of 22x—while posting -2.0% revenue growth, the market is pricing in little optimism.
Key Metrics
- Forward P/E: 9.7x
- Revenue Growth: -0.0%
- 52-Week High: $15.93
- 52-Week Low: $7.26
Analyst Consensus
3 Buy · 15 Hold · 6 Sell (24 analysts)
Bull Case
At 9.7x forward earnings, you're paying a deep discount for a business with entrenched customer relationships if demand stabilizes.
Bear Case
The -2.0% revenue decline suggests that even at a low multiple, further weakness could lead to a value trap and multiple contraction.
Catalyst to Watch
Watch for stabilization or recovery in revenue growth—any positive inflection could spark a rerating from this low base.